AR097931A1 - Derivados de diazacarbazol como ligandos de tau para pet - Google Patents

Derivados de diazacarbazol como ligandos de tau para pet

Info

Publication number
AR097931A1
AR097931A1 ARP140103712A ARP140103712A AR097931A1 AR 097931 A1 AR097931 A1 AR 097931A1 AR P140103712 A ARP140103712 A AR P140103712A AR P140103712 A ARP140103712 A AR P140103712A AR 097931 A1 AR097931 A1 AR 097931A1
Authority
AR
Argentina
Prior art keywords
aggregates
dipyrido
pyridin
pyrrole
fluoro
Prior art date
Application number
ARP140103712A
Other languages
English (en)
Inventor
Gobbi Luca
Knust Henner
Koerner Matthias
Muri Dieter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR097931A1 publication Critical patent/AR097931A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a un compuesto de fórmula general (1) en la que R es hidrógeno o tritio; F es flúor o ¹⁸flúor; o a una sal de adición de ácido farmacéuticamente aceptable. Los compuestos de fórmula (1) incluyen 2-(6-fluoro-piridin-3-il)-9H-dipirido[2,3-b;3,4-d]pirrol, ³H-2-(6-fluoro-piridin-3-il)-9H-dipirido[2,3-b;3,4-d]pirrol y [18F]-2-(6-fluoro-piridin-3-il)-9H-dipirido[2,3-b;3,4-d]pirrol. Los compuestos se pueden usar para la unión y la formación de imágenes de agregados de tau y los agregados de lámina b relacionados incluyendo entre otros agregados de b-amiloide o agregados de a-sinucleína.
ARP140103712A 2013-10-08 2014-10-06 Derivados de diazacarbazol como ligandos de tau para pet AR097931A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13187764 2013-10-08

Publications (1)

Publication Number Publication Date
AR097931A1 true AR097931A1 (es) 2016-04-20

Family

ID=49301396

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103712A AR097931A1 (es) 2013-10-08 2014-10-06 Derivados de diazacarbazol como ligandos de tau para pet

Country Status (33)

Country Link
US (2) US10004817B2 (es)
EP (1) EP3055308B1 (es)
JP (1) JP6194416B2 (es)
KR (1) KR101770531B1 (es)
CN (1) CN105358558B (es)
AR (1) AR097931A1 (es)
AU (1) AU2014333996B2 (es)
CA (1) CA2917191C (es)
CL (1) CL2016000728A1 (es)
CR (1) CR20150663A (es)
DK (1) DK3055308T3 (es)
EA (1) EA028483B1 (es)
ES (1) ES2657121T3 (es)
HK (1) HK1215574A1 (es)
HR (1) HRP20180049T1 (es)
HU (1) HUE035413T2 (es)
IL (1) IL243249A0 (es)
LT (1) LT3055308T (es)
MA (1) MA38935B1 (es)
MX (1) MX2016002234A (es)
MY (1) MY190196A (es)
NO (1) NO3055308T3 (es)
PE (1) PE20160159A1 (es)
PH (1) PH12016500249B1 (es)
PL (1) PL3055308T3 (es)
PT (1) PT3055308T (es)
RS (1) RS56777B1 (es)
SG (1) SG11201602786UA (es)
SI (1) SI3055308T1 (es)
TW (1) TWI513698B (es)
UA (1) UA116164C2 (es)
WO (1) WO2015052105A1 (es)
ZA (1) ZA201509013B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2907992T3 (es) 2008-02-14 2022-04-27 Lilly Co Eli Agentes novedosos de obtención de imágenes para detectar disfunciones neurológicas
EP3055308B1 (en) 2013-10-08 2017-11-22 F.Hoffmann-La Roche Ag Diazacarbazole derivatives as tau-pet-ligands
CN110483522B (zh) * 2014-05-13 2022-05-03 豪夫迈·罗氏有限公司 氘化杂环化合物和其作为成像剂的用途
MX2017009505A (es) * 2015-02-02 2017-11-02 Ucb Biopharma Sprl Derivados de 9h-pirrolo-dipiridina.
EP3322707A1 (en) 2015-07-15 2018-05-23 AC Immune SA Novel imaging compounds
EP3118202A1 (en) 2015-07-15 2017-01-18 AC Immune S.A. Dihydropyridopyrrole derivatives as tau-pet-ligands
US10865207B2 (en) 2016-07-22 2020-12-15 Ac Immune S.A. Compounds for imaging Tau protein aggregates
JP7197476B2 (ja) 2016-07-22 2022-12-27 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
WO2018024642A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
WO2018024643A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
SI3510031T1 (sl) 2016-09-09 2021-03-31 F. Hoffmann-La Roche Ag Postopek za pripravo 2-(6-nitropiridin-3-il)-9H-dipirido(2,3-b;3',4'-d)pirola
US11306089B2 (en) 2018-01-24 2022-04-19 Life Molecular Imaging Limited Gamma-carboline compounds for the detection of Tau aggregates
EA202091767A1 (ru) 2018-01-24 2021-02-16 Ац Иммуне Са Новый способ получения визуализирующего соединения
CN111712265B (zh) * 2018-01-24 2024-02-09 Ac免疫有限公司 用于pet显像的诊断组合物、该诊断组合物的制备方法及其在诊断中的用途
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
ES2907992T3 (es) * 2008-02-14 2022-04-27 Lilly Co Eli Agentes novedosos de obtención de imágenes para detectar disfunciones neurológicas
KR101764556B1 (ko) 2008-06-11 2017-08-02 제넨테크, 인크. 디아자카르바졸 및 사용 방법
JP2011529086A (ja) * 2008-07-24 2011-12-01 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド Ad病変を同定するために有用な造影剤
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
US20150368244A1 (en) * 2011-01-31 2015-12-24 Genentech, Inc. Diazacarbazoles and methods of use
EP3055308B1 (en) 2013-10-08 2017-11-22 F.Hoffmann-La Roche Ag Diazacarbazole derivatives as tau-pet-ligands

Also Published As

Publication number Publication date
EP3055308B1 (en) 2017-11-22
LT3055308T (lt) 2018-02-12
PL3055308T3 (pl) 2018-03-30
CL2016000728A1 (es) 2016-11-11
US20180326099A1 (en) 2018-11-15
EA201690515A1 (ru) 2016-07-29
MA38935B1 (fr) 2016-12-30
RS56777B1 (sr) 2018-04-30
KR20160047552A (ko) 2016-05-02
KR101770531B1 (ko) 2017-08-22
JP6194416B2 (ja) 2017-09-06
CN105358558B (zh) 2017-09-26
MA38935A1 (fr) 2016-04-29
TWI513698B (zh) 2015-12-21
NO3055308T3 (es) 2018-04-21
PE20160159A1 (es) 2016-03-18
ZA201509013B (en) 2016-10-26
PH12016500249A1 (en) 2016-05-16
AU2014333996A1 (en) 2015-12-24
US11058781B2 (en) 2021-07-13
UA116164C2 (uk) 2018-02-12
AU2014333996B2 (en) 2018-03-15
PT3055308T (pt) 2018-01-18
CN105358558A (zh) 2016-02-24
HRP20180049T1 (hr) 2018-02-09
NZ714831A (en) 2021-09-24
CA2917191C (en) 2021-08-10
MX2016002234A (es) 2016-06-06
EA028483B1 (ru) 2017-11-30
TW201520212A (zh) 2015-06-01
IL243249A0 (en) 2016-02-29
SI3055308T1 (en) 2018-03-30
US20160220712A1 (en) 2016-08-04
MY190196A (en) 2022-04-04
JP2016534979A (ja) 2016-11-10
HUE035413T2 (en) 2018-05-02
HK1215574A1 (zh) 2016-09-02
CR20150663A (es) 2016-01-27
EP3055308A1 (en) 2016-08-17
WO2015052105A1 (en) 2015-04-16
CA2917191A1 (en) 2015-04-16
ES2657121T3 (es) 2018-03-01
US10004817B2 (en) 2018-06-26
PH12016500249B1 (en) 2016-05-16
DK3055308T3 (en) 2018-01-22
SG11201602786UA (en) 2016-05-30

Similar Documents

Publication Publication Date Title
AR097931A1 (es) Derivados de diazacarbazol como ligandos de tau para pet
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CR20150045A (es) Inhibidores de hepatitis c
CR20140275A (es) Triazolopiridinas sustituidas
CU20140110A7 (es) Compuestos heterocíclicos como inhibidores de mek
ECSP13013011A (es) Triazolopiridinas
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
AR083870A1 (es) Inhibidores de la replicacion del vih
EA201291414A1 (ru) Имидазопиридиновые производные, способ их получения и терапевтическое использование
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
AR094959A1 (es) Compuestos de imidazo piridina
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
UY33452A (es) Triazolopiridinas sustituidas
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR097739A1 (es) Imidazo[1,2-a]piridina-7-aminas
CO6741154A2 (es) Compuestos de triazolopiridina
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
BR112015023161A2 (pt) derivados de piridin-4-ila
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina

Legal Events

Date Code Title Description
FG Grant, registration